"The Steroid Market Has Collapsed | Janoshik Reveals Why" (see the link at the end of this post for the full video).
NOTE: The following content is a copy/paste of information I found posted in a Telegram group. Credit to whomever authored this summary; it is not my work. All I did was copy the text into a translator to convert it to English to share with everyone. I cannot guarantee the accuracy of the translation.
"It has never been this bad": expert confessions.
Peter Madzhik, founder of the Janoshik Analytical laboratory (testing steroids and peptides worldwide since 2016), gave an interview to reveal the truth about the current state of the underground steroid market. His position is crystal clear: the flow of reliable raw materials has dried up, replaced by substitutions, empty batches, and dangerous counterfeits that are massively making their way into final products. This is not an exaggeration or a theoretical threat — these are everyday results from laboratory tests, where "out of twenty samples, not a single one turns out to be a steroid", and in oils and tablets instead of active substances they find vitamin E or paracetamol.
The shortage began with blows to a key point in the global supply chain — China. There, arrests affected major nodes of steroid raw material production and intermediaries, which instantly cooled the market participants' desire to store warehouses and restart production lines. The result is a sharp drop in direct shipments: according to independent analytics, the share of Chinese anabolic test requests fell to 5–10% of previous years' levels, and neither India, Turkey, nor other sites could quickly replace the capacity. Historical context confirms China's significant role: even during the Raw Deal operation, a significant portion of seized powders originated from China, and any disruption there predictably affected the quality of the final product worldwide.
When the raw material foundation collapses, the problem front shifts to finished forms. Manufacturers, testing only part of a batch, fail to detect duds and "spread" them across the entire range of oils and tablets. This forms an avalanche of duds, substitutions, and underdosing, which reaches the end user in the form of attractive packaging but without the expected pharmacological content. "It has never been this bad", emphasizes the analyst: the sports community faces rising prices, narrowing assortment, and systemic decline in quality predictability, which starts not only at the packagers' level but also "from below," due to the destruction of the raw material base.
At the same time, the volume of peptides is growing — especially GLP1 for weight loss. They now make up 70–80% of incoming tests, while steroids account for 20–30%. However, the external flawlessness of products does not guarantee safety: cases of counterfeit injectable "pens" have been recorded, where insulin was found instead of the declared tirzepatide, posing a risk of severe hypoglycemia. Regulators also confirm this threat, warning about counterfeit batches on the market.
The main principle Madzhik formulates for the sports community is prioritizing health over experiments. New "trendy" compounds without a long observation history create unjustified risks: the desire for rapid progress should not replace the requirements for effect predictability and safety profile. In conditions of raw material crisis and aggressive counterfeiting, a conservative approach is not caution for caution's sake but a reasonable risk reduction strategy, confirmed by daily analytics of samples worldwide. This year, Janoshik Analytical laboratory conducted testing of PHARMACOM products and all declared indicators were confirmed by certified results, which are available in the FC Telegram group.
